Teva Pharmaceutical Industries Limited Release: New Clinical Insights and Data Presented at 29th ECTRIMS Congress Further Advance Teva’s Leadership in Multiple Sclerosis

Published: Sep 26, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that key data from the Company’s multiple sclerosis (MS) franchise will be featured in over 20 presentations at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5, 2013. Data presentations will provide new clinical insights on the effects of treatment with COPAXONE® (glatiramer acetate injection), the world’s leading relapsing-remitting multiple sclerosis (RRMS) treatment, and the novel effects of laquinimod, Teva’s investigational oral compound, when used to treat RRMS.

Help employers find you! Check out all the jobs and post your resume.

Back to news